Short acting GLP-1 receptor agonist (injectable)
Exenatide 2.5 µg injection twice daily
EXEN_SC_2p5UG_BID
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.07 (0.41 to 2.72) | 0.60 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 5.22 (0.20 to 142) | 0.18 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.57 (0.41 to 4.84) | 0.66 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.29 (0.20 to 5.61) | 0.68 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.58 (0.05 to 3.52) | 0.78 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.87 (0.47 to 6.34) | 0.45 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.86 (0.05 to 13.28) | 0.47 |